Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 3Completed 2Terminated 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Other solid neoplasm 1Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Myelodysplastic Syndromes 26Lymphoma, Non-Hodgkin 20Hematologic Neoplasms 20Lymphoma 19Multiple Myeloma 18Lymphoma, B-Cell 15Recurrence 14Lymphoma, Large B-Cell, Diffuse 13Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Breast Neoplasms 11Pancreatic Neoplasms 10Lymphoma, Follicular 10Ovarian Neoplasms 9Melanoma 9Leukemia, Myelomonocytic, Chronic 9Neoplasm Metastasis 8Myeloproliferative Disorders 8Stomach Neoplasms 7Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 7Leukemia, Biphenotypic, Acute 7Leukemia 7Hodgkin Disease 7Glioblastoma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 6

Interventions

Oxaliplatin 13Bevacizumab 11Capecitabine 10Fluorouracil 8Blood Specimen Collection 8Leucovorin 7Cetuximab 7Folfox protocol 6pembrolizumab 5Drug Therapy 5trifluridine tipiracil drug combination 4dostarlimab 4Nivolumab 4Irinotecan 4HMPL-013 4fludarabine 3XELOX 3Specimen Handling 3IFL protocol 3Cyclophosphamide 3Biopsy 3toripalimab 2tislelizumab 2tipiracil 2regorafenib 2pertuzumab 2envafolimab 2encorafenib 2cemiplimab 2atezolizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Colonic Neoplasms × fludarabine × Clear all
NCT03190941 2026-05-22

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
110 enrolled
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT06885697 2026-02-17

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
100 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Colonic Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thymoma, Thymus Neoplasms

NCT06530303 2024-11-05

BAH248

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡